systemic juvenile idiopathic arthritis
Rheumatology · 2011–2025
No submission for this condition has carried consumer input, including the 3 made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| tocilizumab Tocilizumab biosimilar requested for listing under the same indications as the reference biologic Actemra, including active giant cell arteritis, systemic… | Nov 2025 | Recommended with restriction | none received |
| tocilizumab Treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients 1 year of age and older, as an extension to existing subcutaneous presentations. | Mar 2020 | Recommended with restriction | unclear |
| canakinumab Treatment of systemic juvenile idiopathic arthritis (sJIA) in patients aged 2 years and older with active systemic manifestations who have failed to respond to… | Mar 2015 | Not recommended | none received |
| tocilizumab Treatment of severe active systemic juvenile idiopathic arthritis in patients under 18 years of age who have failed or are intolerant to methotrexate or other… | Nov 2011 | Recommended with restriction | no section in document |
What the PBS pays
$70M in government benefit over 2024–25, across 91,499 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| tocilizumab | $69.8M |
Appraised elsewhere
NICE, in England and Wales, has appraised 2 technologies for this condition, recommending 0 and declining 1. A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.